Depressive DisordersAnxiety DisordersSuicidality

Psychedelic Use Among Psychiatric Medication Prescribers: Effects on Well-Being, Depression, Anxiety, and Associations with Patterns of Use, Reported Harms, and Transformative Mental States

This cross-sectional online survey (n=228) examined the effects of psychedelic use on healthcare providers who treat psychiatric disorders with medications. The study found that psychedelic use was associated with improvements in depression, anxiety, well-being, and resilience, and a decrease in reported suicidality. A factor analysis indicated that a combination of mystical, interpersonal, and personal experiences predicted these improvements. The preferred psychedelic agent did not influence outcomes, and frequency of use showed varied effect sizes. While 13.2% (n=30) reported at least one harm from psychedelic use, the results suggest potential benefits for healthcare providers, consistent with findings from other studies on the general population.

Authors

  • Charles Raison
  • Brian Barnett

Published

Psychedelic Medicine
individual Study

Abstract

Mental health problems including depression, anxiety, suicide, and burnout are common among health care providers. Resilience and well-being are factors thought to protect against these incidents. Clinical trials and naturalistic studies of psychedelic compounds have shown decreases in depression, anxiety, and suicidality while suggesting improvements in well-being. This secondary analysis of a large cross-sectional online survey consisting of participants with at least one lifetime psychedelic use sought to examine how use affects health care providers who treat psychiatric disorders with medications. In total, 228 respondents retrospectively completed measures of depression, anxiety, and well-being before and after psychedelic exposure. They also reported lifetime use, harms attributed to use, and preferred psychedelic agent. Psychedelic use was associated with improvements in depression, anxiety, and well-being. Reported suicidality decreased and resilience increased. A factor analysis suggested that a cluster of mystical, interpersonal, and personal items predicted improvement in depression, anxiety, well-being, suicidality, and resilience. Preferred psychedelic agent did not affect outcomes. Frequency of use was not associated with outcomes although differences in effect sizes were seen. Harm reported was consistent with the general population, with 13.2% (n = 30) reporting at least one harm. Pre-exposure alcohol use, aggressive impulses, and desire to die by suicide improved most often while marijuana use most often worsened or did not change. These results are consistent with clinical trials and naturalistic studies examining psychedelic use in the general population and suggest that health care providers who treat psychiatric disorders with medications may benefit from psychedelic use, although some harm was reported. Given the current mental health crisis among health care providers, further research is warranted to examine whether interventions utilizing psychedelics could improve well-being and effectiveness of health care providers while decreasing adverse mental health outcomes associated with working in health care.

Available with Blossom Pro

Research Summary of 'Psychedelic Use Among Psychiatric Medication Prescribers: Effects on Well-Being, Depression, Anxiety, and Associations with Patterns of Use, Reported Harms, and Transformative Mental States'

Introduction

Herrmann and colleagues frame their study within a recognised mental health crisis among health care workers, noting high rates of depression, anxiety, burnout and suicide that have been exacerbated by the COVID-19 pandemic. Earlier research and recent clinical trials suggest that psychedelic-assisted therapies and naturalistic psychedelic use can reduce symptoms of depression and anxiety, lower suicidality, and improve aspects of well-being and resilience in general populations. The authors highlight that little is known about how naturalistic psychedelic use affects clinicians who prescribe psychiatric medications, partly because of concerns about professional and legal repercussions that discourage disclosure. This paper reports a secondary analysis of data from the larger Psychedelics and Wellness Study (PAWS). The specific aim was to examine retrospective self-reported changes in depression, anxiety, emotional well-being, resilience and suicidal ideation among prescribers of psychiatric medication who have used psychedelics at least once. Secondary aims included exploring associations with lifetime use patterns, preferred psychedelic agent, and harms attributed to use. The authors hypothesised that respondents would generally report improvements on the assessed measures and that harms would be less common.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Study Details

  • Study Type
    individual
  • Journal
  • Topics
  • Authors
  • APA Citation

    Herrmann, Z., Levin, A. W., Cole, S. P., Slabaugh, S., Barnett, B., Penn, A., Jain, R., Raison, C., Rajanna, B., & Jain, S. (2023). Psychedelic Use Among Psychiatric Medication Prescribers: Effects on Well-Being, Depression, Anxiety, and Associations with Patterns of Use, Reported Harms, and Transformative Mental States. Psychedelic Medicine, 1(3), 139-149. https://doi.org/10.1089/psymed.2023.0030

References (31)

Papers cited by this study that are also in Blossom

Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders

Vollenweider, F. X., Preller, K. H. · Nature Reviews Neuroscience (2020)

Scoping Review of Experiential Measures from Psychedelic Research and Clinical Trials

Herrmann, Z., Earleywine, M., De Leo, J. et al. · Journal of Psychoactive Drugs (2022)

Trial of Psilocybin versus Escitalopram for Depression

Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)

927 cited
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression

Goodwin, G. M., Aaronson, S. T., Alvarez, O. et al. · New England Journal of Medicine (2022)

656 cited
Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer

Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)

Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study

Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)

Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)

Long-term follow-up of psilocybin-facilitated smoking cessation

Johnson, M. W., Garcia-Romeu, A., Griffiths, R. R. · The American Journal of Drug and Alcohol Abuse (2016)

562 cited
Show all 31 references
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study

Mitchell, J., Bogenschutz, M. P., Lilienstein, A. et al. · Nature Medicine (2021)

Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample

Nygart, V., Pommerencke, L. M., Haijen, E. et al. · Journal of Psychopharmacology (2022)

46 cited
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects

Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Psychopharmacology (2011)

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)

Predicting responses to psychedelics: a prospective study

Haijen, E. C. H. M., Kaelen, M., Roseman, L. et al. · Frontiers in Pharmacology (2018)

339 cited
Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population

Hendricks, P. S., Thorne, C. B., Clark, B. et al. · Journal of Psychopharmacology (2015)

345 cited
Lysergic acid diethylamide: side effects and complications

Cohen, S. · Journal of Nervous and Mental Disease (1980)

143 cited
Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review

Knight, G., Rucker, J., Cleare, A. J. et al. · Frontiers in Psychiatry (2022)

Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report

McCulloch, D. E-W., Madsen, M. K., Jensen, P. S. et al. · Frontiers in Pharmacology (2022)

79 cited
How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change

Zeifman, R. J., Wagner, A. C., Monson, C. M. et al. · Journal of Affective Disorders (2023)

47 cited
A Survey of American Psychiatrists’ Attitudes Toward Classic Hallucinogens

Barnett, B. S., Siu, W. O., Pope Jr, H. G. · Journal of Nervous and Mental Disease (2018)

The readiness of psychiatrists to implement psychedelic-assisted psychotherapy

Page, L., Rehman, A., Syed, H. et al. · Frontiers in Psychiatry (2021)

30 cited

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.